PRTO Proteon Therapeutics Inc.

3
+0.03  (+1%)
Previous Close 2.97
Open 2.97
Price To Book 17.65
Market Cap 57663876
Shares 19,221,292
Volume 247,758
Short Ratio
Av. Daily Volume 94,337

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 13, 2016 - primary endpoint not met.
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 data due March 2019.
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 1 enrollment to be completed 4Q 2018.
Vonapanitase (PRT-201)
Peripheral artery disease (PAD)